AIVITA Biomedical, Inc.
Tuesday, February 27, 2024
AIVITA Biomedical is a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer. We take a unique pan-antigenic approach for our cancer vaccine — targeting all neoantigens, rather than a select few — allowing our treatment to overcome cancer’s tendency to mutate over time. Utilizing our autologous cell therapy platform, we are developing a personalized vaccine for with adaptive immunity against infectious disease. Our unique expertise in stem cell growth and directed, high-purity differentiation enables us to develop safe, efficient and economical manufacturing processes for therapeutic development. Our patient-specific treatments in cancer have shown tremendous promise in eradicating tumors without harmful side effects in our melanoma, glioblastoma and ovarian cancer clinical studies. Our personalized vaccine for COVID-19 demonstrated a 97% T-cell response against the most current strains.
CEO/Top Company Official
Hans Keirstead, Ph.D.
Lead Product in Development
Ph3 cancer immunotherapy in GBM and Melanoma. We also have a commercially available vaccine kit.
Development Phase of Primary Product
Number Of Unlicensed Products